Savara Inc Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Savara Inc stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $194.00K, a 198.46% increase year-over-year.
- Savara Inc stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $45.00K, a 72.73% decline year-over-year.
- Savara Inc stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $65.00K, a 490.91% increase year-over-year.
- Savara Inc stock issued during period, value, stock options exercised for the quarter ending 2025-03-31 was $165.00K, a 223.53% increase year-over-year.
- Savara Inc stock issued during period, value, stock options exercised for fiscal 2025 was $347.00K, a 0.00% change from fiscal 2024.
- Savara Inc stock issued during period, value, stock options exercised for fiscal 2024 was $347.00K, a 22.61% increase from fiscal 2023.
- Savara Inc stock issued during period, value, stock options exercised for fiscal 2023 was $283.00K, a 14050.00% increase from fiscal 2022.
- Savara Inc stock issued during period, value, stock options exercised for fiscal 2022 was $2.00K, a 87.50% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $194.00K 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $45.00K 10-Q · filed 2026-08-11 | |
| 2025-12-31 | $347.00K 10-K · filed 2026-03-13 | |
| 2025-06-30 | $65.00K 10-Q · filed 2026-08-11 | |
| 2025-03-31 | $165.00K 10-Q · filed 2026-08-11 | |
| 2024-12-31 | $347.00K 10-K · filed 2026-03-13 | |
| 2024-09-30 | $237.00K 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $11.00K 10-Q · filed 2025-11-12 | |
| 2024-03-31 | $51.00K 10-Q · filed 2025-11-12 | |
| 2023-12-31 | $283.00K 10-K · filed 2025-03-27 | |
| 2023-09-30 | $64.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $103.00K 10-Q · filed 2024-11-12 | |
| 2023-03-31 | $27.00K 10-Q · filed 2024-11-12 | |
| 2022-12-31 | $2.00K 10-K · filed 2024-03-07 | |
| 2021-12-31 | $16.00K 10-K · filed 2023-03-30 | |
| 2021-09-30 | $10.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $3.00K 10-Q · filed 2022-11-10 | |
| 2021-03-31 | $2.00K 10-Q · filed 2022-11-10 | |
| 2020-12-31 | $88.00K 10-K · filed 2022-03-30 | |
| 2020-06-30 | $39.00K 10-Q · filed 2021-11-12 | |
| 2020-03-31 | $48.00K 10-Q · filed 2021-11-12 | |
| 2019-12-31 | $111.00K 10-K · filed 2021-03-10 | |
| 2019-09-30 | $45.00K 10-Q · filed 2020-11-05 | $120.00K derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | $61.00K 10-Q · filed 2020-11-05 | $92.00K derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-03-31 | $6.00K 10-Q · filed 2020-11-05 | $61.00K derived: sum of 4 quarters · filed 2020-11-05 |
| 2018-12-31 | $8.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $58.00K 10-K · filed 2020-03-12 |
| 2018-09-30 | $17.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | |
| 2018-06-30 | $30.00K 10-Q · filed 2019-11-07 | |
| 2018-03-31 | $3.00K 10-Q · filed 2019-11-07 | |
| 2017-12-31 | $5.00K 10-K · filed 2019-03-13 | |
| 2016-12-31 | $1.00K 10-K · filed 2018-03-14 | |
| 2012-12-31 | $2.19K 10-K · filed 2014-03-26 | |
| 2007-12-31 | $441.62K 10-K · filed 2014-03-26 | |
| 2006-12-31 | $125.75K 10-K · filed 2014-03-26 | |
| 2005-12-31 | $145.00K 10-K · filed 2014-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |